Clinical Review Lesson of the week

Congenital neonatal thyrotoxicosis and previous maternal radioiodine therapy

BMJ 2000; 320 doi: https://doi.org/10.1136/bmj.320.7244.1260 (Published 06 May 2000) Cite this as: BMJ 2000;320:1260
  1. C M Smith, senior registrara,
  2. J Gavranich, staff paediatricianb,
  3. A Cotterill, director of paediatric endocrinologya,
  4. C P Rodda, paediatric endocrinologist ([email protected])c
  1. a Mater Children's Hospital, South Brisbane, Queensland 4101, Australia
  2. b Ipswich Hospital, Ipswich, Queensland 4305, Australia
  3. c Department of Paediatrics, Monash University, Monash Medical Centre, Clayton, Victoria 3168, Australia
  1. Correspondence to: C P Rodda
  • Accepted 23 August 1999

Maternal radioiodine therapy does not protect against congenital thyrotoxicosis—a blood test helps to predict those at risk

The risk of congenital thyrotoxicosis may well be apparent when a pregnant woman has florid thyrotoxic Graves' disease (figure). A maternal history of Graves' disease, however, may be overlooked, especially if the mother is taking thyroxine replacement after radioablation or surgery. Maternal thyroid stimulating antibodies may persist,1 and consequently a woman's newborn infant is still at risk. Thyroid stimulating antibodies can be quantified by measuring the “thyroid stimulating hormone binding inhibiting immunoglobulin” (TBI) index.2 This competitive radioreceptor assay measures binding to a porcine thyroid stimulating hormone receptor of the patient's immunoglobulin, compared with labelled thyroid stimulating hormone. A high maternal TBI index is a useful measure to indicate increased likelihood of disease developing in the infant. Although certain prediction of an infant being affected is not possible antenatally,2 2-44 a maternal TBI index of more than 30 units predicts, and more than 70 units strongly predicts, that the infant will be more likely to be affected. Therefore all infants of mothers with a history of Graves' disease must be carefully monitored, both clinically and biochemically, for up to seven days postnatally.

An affected child (bottom) of a floridly thyrotoxic mother (top). Both have goitres. Published with mother's permission

Although Graves' disease complicates 0.1-0.2% of all pregnancies, congenital thyrotoxicosis is rare, occurring in 1 in 70 of these pregnancies, and its development may be irrespective of either maternal disease or antibody status alone. Congenital thyrotoxicosis is transient, lasting up to three months or more, and is due to the transplacental passage of the stimulating (infrequently inhibitory) maternal antibodies of the IgG class, which may cause substantial neonatal morbidity or …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe